FDA intends to design regulatory standards for large-scale compounding manufacturers, rather than subject them to all current Good Manufacturing Practices, if a draft Senate bill to expand agency oversight of the industry is enacted.
Questions remain, however, about whether the additional oversight proposed in the bill should go into effect right away or after...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?